Cryopreserved Assay-Ready Cells Paper Published

We're thrilled to announce that one of our leading scientists have published a research paper which highlights advancements in the cryopreservation of assay-ready cells. We've demonstrated how controlled ice nucleation leads to reproducible frozen storage of hepatocyte monolayers. These cells can be directly retrieved from the freezer and utilized without any additional manipulating. We've validated that their performance matches that of fresh cells in multiple toxicology tests. Furthermore, we've extended these findings to primary cells. This foundational technology has been optimized by CryoLogyx to produce assay-ready cells, encompassing our ToxReady™ series. 


Read the abstract below, or the full paper here.

Cell culture plays a critical role in biomedical discovery and drug development. Primary hepatocytes and hepatocyte-derived cell lines are especially important cellular models for drug discovery and development. To enable high-throughput screening and ensure consistent cell phenotypes, there is a need for practical and efficient cryopreservation methods for hepatocyte-derived cell lines and primary hepatocytes in an assay-ready format. Cryopreservation of cells as adherent monolayers in 96-well plates presents unique challenges due to low volumes being susceptible to supercooling, leading to low recovery and well-to-well variation. Primary cell cryopreservation is also particularly challenging due to the loss of cell viability and function. In this study, we demonstrate the use of soluble ice nucleator materials (IN) to cryopreserve a hepatic-derived cell line (HepG2) and primary mouse hepatocytes, as adherent monolayers. HepG2 cell recovery was near 100% and ∼75% of primary hepatocytes were recovered 24 hours post-thaw compared to just 10% and 50% with standard 10% DMSO, respectively. Post-thaw assessment showed that cryopreserved HepG2 cells retain membrane integrity, metabolic activity, proliferative capacity and differentiated hepatic functions including urea secretion, cytochrome P450 levels and lipid droplet accumulation. Cryopreserved primary hepatocytes exhibited reduced hepatic functions compared to fresh hepatocytes, but functional levels were similar to commercial suspension-cryopreserved hepatocytes, with the added benefit of being stored in an assay-ready format. In addition, normal cuboidal morphology and minimal membrane damage were observed 24 hours post-thaw. Cryopreserved HepG2 and mouse hepatocytes treated with a panel of pharmaceutically active compounds produced near-identical dose–response curves and EC50 values compared to fresh hepatocytes, confirming the utility of cryopreserved bankable cells in drug metabolism and hepatotoxicity studies. Cryopreserved adherent HepG2 cells and primary hepatocytes in 96 well plates can significantly reduce the time and resource burden associated with routine cell culture and increases the efficiency and productivity of high-throughput drug screening assays. 


Stay tuned for more updates as we continue to push the boundaries of cell cryopreservation! 

Follow us on LinkedIn.


This journal is © The Royal Society of Chemistry 2023 

Previous
Previous

Unboxing with us!

Next
Next

Thank You for Making Drug Discovery 2023 a Resounding Success!